JP2011519865A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011519865A5 JP2011519865A5 JP2011507641A JP2011507641A JP2011519865A5 JP 2011519865 A5 JP2011519865 A5 JP 2011519865A5 JP 2011507641 A JP2011507641 A JP 2011507641A JP 2011507641 A JP2011507641 A JP 2011507641A JP 2011519865 A5 JP2011519865 A5 JP 2011519865A5
- Authority
- JP
- Japan
- Prior art keywords
- carbon atoms
- group
- compound
- ring
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004432 carbon atom Chemical group C* 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 22
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 15
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims 14
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims 14
- 125000003545 alkoxy group Chemical group 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 14
- 229940116269 uric acid Drugs 0.000 claims 14
- 150000002431 hydrogen Chemical class 0.000 claims 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 11
- -1 perfluoromethoxy Chemical group 0.000 claims 11
- 125000001309 chloro group Chemical group Cl* 0.000 claims 9
- 125000001153 fluoro group Chemical group F* 0.000 claims 9
- 125000001246 bromo group Chemical group Br* 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 7
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000006413 ring segment Chemical group 0.000 claims 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000029142 excretion Effects 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- JYXZNKDUAFJFDE-UHFFFAOYSA-N 5-[2-[3-[(2,6-dimethylphenyl)methoxy]phenyl]ethyl]-2h-tetrazole Chemical compound CC1=CC=CC(C)=C1COC1=CC=CC(CCC=2NN=NN=2)=C1 JYXZNKDUAFJFDE-UHFFFAOYSA-N 0.000 claims 2
- MQPHXULSDFCNPQ-UHFFFAOYSA-N 5-[3-[(2,6-dimethylphenyl)methoxy]phenyl]-2h-tetrazole Chemical compound CC1=CC=CC(C)=C1COC1=CC=CC(C=2NN=NN=2)=C1 MQPHXULSDFCNPQ-UHFFFAOYSA-N 0.000 claims 2
- FAKRBAIVHKBWNT-UHFFFAOYSA-N 5-[[3-[(2,6-dimethylphenyl)methoxy]-2-methoxyphenyl]methyl]-2h-tetrazole Chemical compound C1=CC=C(OCC=2C(=CC=CC=2C)C)C(OC)=C1CC1=NN=NN1 FAKRBAIVHKBWNT-UHFFFAOYSA-N 0.000 claims 2
- NHXKOJIELXSYQN-UHFFFAOYSA-N 5-[[3-[(2,6-dimethylphenyl)methoxy]-2-methylphenyl]methyl]-2h-tetrazole Chemical compound CC1=CC=CC(C)=C1COC1=CC=CC(CC=2NN=NN=2)=C1C NHXKOJIELXSYQN-UHFFFAOYSA-N 0.000 claims 2
- CWUFRHCAHLQODO-UHFFFAOYSA-N 5-[[3-[(2,6-dimethylphenyl)methoxy]-4-methoxyphenyl]methyl]-2h-tetrazole Chemical compound C1=C(OCC=2C(=CC=CC=2C)C)C(OC)=CC=C1CC1=NN=NN1 CWUFRHCAHLQODO-UHFFFAOYSA-N 0.000 claims 2
- PVTBFAKZJRWPNC-UHFFFAOYSA-N 5-[[3-[(2,6-dimethylphenyl)methoxy]-4-methylphenyl]methyl]-2h-tetrazole Chemical compound C1=C(OCC=2C(=CC=CC=2C)C)C(C)=CC=C1CC1=NN=NN1 PVTBFAKZJRWPNC-UHFFFAOYSA-N 0.000 claims 2
- KJVQFGWUVANOSW-UHFFFAOYSA-N 5-[[3-[(2,6-dimethylphenyl)methoxy]phenyl]methyl]-2h-tetrazole Chemical compound CC1=CC=CC(C)=C1COC1=CC=CC(CC=2NN=NN=2)=C1 KJVQFGWUVANOSW-UHFFFAOYSA-N 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 201000001431 Hyperuricemia Diseases 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- YYRQECAOVDIPKD-UHFFFAOYSA-N 5-[[4-[(2,6-difluorophenyl)methoxy]phenyl]methyl]-2h-tetrazole Chemical compound FC1=CC=CC(F)=C1COC(C=C1)=CC=C1CC1=NN=NN1 YYRQECAOVDIPKD-UHFFFAOYSA-N 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000007530 Essential hypertension Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000000913 Kidney Calculi Diseases 0.000 claims 1
- 206010029148 Nephrolithiasis Diseases 0.000 claims 1
- 241000223960 Plasmodium falciparum Species 0.000 claims 1
- 108010092464 Urate Oxidase Proteins 0.000 claims 1
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002028 premature Effects 0.000 claims 1
- 230000008085 renal dysfunction Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000011287 therapeutic dose Methods 0.000 claims 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4916708P | 2008-04-30 | 2008-04-30 | |
| US61/049,167 | 2008-04-30 | ||
| US9374308P | 2008-09-03 | 2008-09-03 | |
| US61/093,743 | 2008-09-03 | ||
| PCT/US2009/042298 WO2009134995A2 (en) | 2008-04-30 | 2009-04-30 | Tetrazole compounds for reducing uric acid |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011519865A JP2011519865A (ja) | 2011-07-14 |
| JP2011519865A5 true JP2011519865A5 (enExample) | 2013-04-11 |
| JP5431457B2 JP5431457B2 (ja) | 2014-03-05 |
Family
ID=41255799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011507641A Expired - Fee Related JP5431457B2 (ja) | 2008-04-30 | 2009-04-30 | 尿酸を減少させるテトラゾール化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8410154B2 (enExample) |
| EP (1) | EP2282736B1 (enExample) |
| JP (1) | JP5431457B2 (enExample) |
| KR (1) | KR101613611B1 (enExample) |
| CN (1) | CN102014898B (enExample) |
| AU (1) | AU2009243028B2 (enExample) |
| BR (1) | BRPI0910541B8 (enExample) |
| CA (1) | CA2722624C (enExample) |
| ES (1) | ES2561039T3 (enExample) |
| IL (1) | IL209004A (enExample) |
| MX (1) | MX2010011603A (enExample) |
| NZ (1) | NZ588374A (enExample) |
| RU (1) | RU2522458C2 (enExample) |
| WO (1) | WO2009134995A2 (enExample) |
| ZA (1) | ZA201006929B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8829058B2 (en) | 2008-03-13 | 2014-09-09 | Wellstat Therapeutics Corporation | Compounds and method for reducing uric acid |
| MX2010011603A (es) | 2008-04-30 | 2011-01-25 | Wellstat Therapeutics Corp | Compuestos de tetrazol para reducir el acido urico. |
| WO2011046800A1 (en) * | 2009-10-13 | 2011-04-21 | Wellstat Therapeutics Corporation | 3-substituted compounds for reducing uric acid |
| US20130331452A1 (en) | 2010-09-08 | 2013-12-12 | Wellstat Therapeutics Corporation | Benzoic acid compounds for reducing uric acid |
| ES2704233T3 (es) * | 2011-11-03 | 2019-03-15 | Ardea Biosciences Inc | Compuesto de piridina 3,4-di-sustituido, procedimientos de uso y composiciones que comprenden el mismo |
| MX357510B (es) * | 2011-11-04 | 2018-07-12 | Cymabay Therapeutics Inc | Metodos para tratar ataques de gota. |
| WO2013111870A1 (ja) * | 2012-01-27 | 2013-08-01 | 帝人ファーマ株式会社 | 糖尿病の治療薬 |
| TW201443025A (zh) * | 2013-04-19 | 2014-11-16 | Pfizer Ltd | 化學化合物 |
| CN104292176B (zh) * | 2014-10-07 | 2016-06-29 | 张远强 | 一种含卤代苯的四氮唑乙酸类化合物、其制备方法和用途 |
| CN104262277B (zh) * | 2014-10-07 | 2016-06-22 | 张远强 | 含硝基和卤苯取代的四氮唑乙酸类化合物、其制备方法及用途 |
| CN104292177B (zh) * | 2014-10-07 | 2016-08-17 | 张远强 | 含腈基和卤苯取代的四氮唑乙酸类化合物、其制备方法及用途 |
| JP6192142B2 (ja) * | 2016-09-13 | 2017-09-06 | サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 痛風発赤の治療方法 |
| RU2683570C1 (ru) * | 2018-05-23 | 2019-03-29 | Евгений Иванович Верещагин | Композиция из растительных компонентов, обладающая способностью снижать уровень мочевой кислоты сыворотки крови |
| CN111943957B (zh) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | 喹啉甲酰胺类化合物及其制备方法和用途 |
| CN114805233A (zh) * | 2022-03-30 | 2022-07-29 | 华南理工大学 | 苯基四氮唑类xor抑制剂及其制备方法与应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4021556A (en) | 1972-06-08 | 1977-05-03 | Icn Pharmaceuticals, Inc. | Xanthine oxidase inhibitors |
| US4024253A (en) | 1973-04-20 | 1977-05-17 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Treatment of elevated histamine and uric acid levels |
| US4182764A (en) | 1973-10-11 | 1980-01-08 | Merck & Co., Inc. | Tetrazole derivatives of [1-oxo-2-aryl or thienyl-2-substituted-5-indanyloxy(or thio)]alkanoic acids |
| US4874777A (en) | 1987-04-10 | 1989-10-17 | Eli Lilly And Company | Leukotriene antagonists |
| US4845231A (en) | 1988-02-12 | 1989-07-04 | American Home Products Corporation | Tetrazoles and their use as hypoglycemic agents |
| FR2631827B1 (fr) | 1988-05-27 | 1992-03-27 | Delalande Sa | Nouveaux derives d'(hetero)aryl-5 tetrazole, leur procede de preparation et leur application en therapeutique |
| US5260322A (en) | 1990-10-08 | 1993-11-09 | Merck & Co., Inc. | Angiotension II antagonists in the treatment of hyperuricemia |
| US5591862A (en) | 1993-06-11 | 1997-01-07 | Takeda Chemical Industries, Ltd. | Tetrazole derivatives, their production and use |
| RU2144533C1 (ru) * | 1994-12-09 | 2000-01-20 | Такеда Кемикал Индастриз, Лтд. | Производные тетразола, способ их получения и фармацевтические композиции на их основе |
| JP2002503202A (ja) | 1996-02-02 | 2002-01-29 | メルク エンド カンパニー インコーポレーテッド | 抗糖尿病薬 |
| AU9696198A (en) | 1997-10-17 | 1999-05-10 | Aventis Pharmaceuticals Products Inc. | Therapeutic uses of quinoline derivatives |
| EP1127882A1 (en) * | 2000-01-25 | 2001-08-29 | Pfizer Products Inc. | Tetrazole compounds as thyroid receptor ligands |
| RU2341513C2 (ru) | 2001-06-12 | 2008-12-20 | Веллстат Терапьютикс Корпорейшн | Соединения для лечения метаболических заболеваний |
| AU2003226094A1 (en) * | 2002-03-27 | 2003-10-13 | Smithkline Beecham Corporation | Compounds and methods |
| US7078423B2 (en) * | 2002-07-18 | 2006-07-18 | Inotek Pharmaceuticals Corporation | 5-Aryltetrazole compounds, compositions thereof, and uses therefor |
| US7087631B2 (en) * | 2002-07-18 | 2006-08-08 | Inotek Pharmaceuticals Corporation | Aryltetrazole compounds, and compositions thereof |
| JP2004197711A (ja) * | 2002-12-20 | 2004-07-15 | Honda Motor Co Ltd | 回転流体機械 |
| JP2007523842A (ja) * | 2003-03-11 | 2007-08-23 | ノボ ノルディスク アクティーゼルスカブ | 酸安定化されたインスリンを含有する薬学的製剤 |
| AR051780A1 (es) | 2004-11-29 | 2007-02-07 | Japan Tobacco Inc | Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos |
| US8829058B2 (en) | 2008-03-13 | 2014-09-09 | Wellstat Therapeutics Corporation | Compounds and method for reducing uric acid |
| MX2010011603A (es) | 2008-04-30 | 2011-01-25 | Wellstat Therapeutics Corp | Compuestos de tetrazol para reducir el acido urico. |
-
2009
- 2009-04-30 MX MX2010011603A patent/MX2010011603A/es active IP Right Grant
- 2009-04-30 ES ES09739797.0T patent/ES2561039T3/es active Active
- 2009-04-30 CN CN2009801155473A patent/CN102014898B/zh not_active Expired - Fee Related
- 2009-04-30 BR BRPI0910541A patent/BRPI0910541B8/pt not_active IP Right Cessation
- 2009-04-30 CA CA2722624A patent/CA2722624C/en not_active Expired - Fee Related
- 2009-04-30 EP EP09739797.0A patent/EP2282736B1/en active Active
- 2009-04-30 AU AU2009243028A patent/AU2009243028B2/en not_active Ceased
- 2009-04-30 JP JP2011507641A patent/JP5431457B2/ja not_active Expired - Fee Related
- 2009-04-30 US US12/989,724 patent/US8410154B2/en active Active
- 2009-04-30 WO PCT/US2009/042298 patent/WO2009134995A2/en not_active Ceased
- 2009-04-30 KR KR1020107024008A patent/KR101613611B1/ko not_active Expired - Fee Related
- 2009-04-30 RU RU2010148762/04A patent/RU2522458C2/ru active
- 2009-04-30 NZ NZ588374A patent/NZ588374A/xx not_active IP Right Cessation
-
2010
- 2010-09-29 ZA ZA2010/06929A patent/ZA201006929B/en unknown
- 2010-10-28 IL IL209004A patent/IL209004A/en active IP Right Grant
-
2013
- 2013-03-04 US US13/783,680 patent/US8889724B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010148762A (ru) | Тетразольные соединения для снижения концентрации мочевой кислоты | |
| EP2504005B1 (en) | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | |
| JP2008513499A5 (enExample) | ||
| RU2009125019A (ru) | Производные карбоновой кислоты | |
| RU2012110592A (ru) | Соединения и способ снижения мочевой кислоты | |
| JP2009528375A5 (enExample) | ||
| JP2022537570A (ja) | がんを処置する方法 | |
| JP2009531280A5 (enExample) | ||
| CN1155409C (zh) | 用于预防和治疗动脉硬化的药物组合物 | |
| CN1379766A (zh) | 治疗糖尿病的苯甲酸衍生物 | |
| TW201249432A (en) | Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia | |
| RU2005128501A (ru) | Соединение для лечения метаболических расстройств | |
| CN1255059A (zh) | 治疗狗的疼痛和炎症的cox－2选择性咔洛芬 | |
| JP2014502979A5 (enExample) | ||
| JP2009537559A5 (enExample) | ||
| JP2009528275A5 (enExample) | ||
| US20170368007A1 (en) | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | |
| JP2006501201A5 (enExample) | ||
| JP2008534601A5 (enExample) | ||
| EP2532350A1 (en) | Pharmaceutical combination of a glucocorticoid receptor antagonist and a cortisol synthesis inhibitor for treating cushing's syndrome | |
| CA2522738A1 (en) | Compounds for the treatment of metabolic disorders | |
| TW201026684A (en) | Phosphodiesterase type III (PDE III) inhibitors or Ca2+ -sensitizing agents for the treatment of hypertrophic cardiomyopathy | |
| JP2013507438A5 (enExample) | ||
| JP2007519633A5 (enExample) | ||
| JP2004533415A5 (enExample) |